Triple combination therapy lowered HbA1c more than dual therapy in type 2 diabetes

Evidence Suggest

• HbA1c fell more with glimepiride plus voglibose plus extended-release metformin than with either dual-drug comparator at both 12 and 24 weeks.
• By 24 weeks, 62.3% of patients on triple therapy reached HbA1c below 7%, compared with 30.0% and 35.7% in the dual-therapy groups.
• Only two level 1 hypoglycemia events were reported overall, and no serious or severe adverse events occurred.

Who this applies to

These findings apply most directly to adults aged 18 to 65 years with type 2 diabetes in India who remain above target despite stable metformin monotherapy, and who do not have major renal, hepatic, or gastrointestinal exclusion conditions. The results are most relevant to patients with HbA1c between 7.5% and 9.0%.

Keep in Mind

All three treatments improved glucose control, so the main question is the size of the extra benefit from the triple combination. The primary endpoint was an objective lab measure, which strengthens confidence, but the open-label design and industry funding still matter. The study also used fixed-dose combinations and dose uptitration rules that may not fully match every real-world setting.

Between the Lines

• The study was open-label, so participants and clinicians knew which treatment was given.
• The trial included only adults in India with baseline HbA1c up to 9%, so results may not apply to all people with type 2 diabetes.
• Follow-up lasted 24 weeks, so longer-term durability and safety are still uncertain.
• The study was funded by the manufacturer, which increases the need for independent confirmation.